GENinCodeLSE:GENI -2.11% Pretax Margin % is -196.47% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, GENinCode ranks worse than 84.16% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. GENinCode's Pre-Tax Income for the
six
months ended in Dec. 2025 was £-2.90 Mil. GENinCode's Revenue for the
six
months ended in Dec. 2025 was £1.47 Mil. Therefore, GENinCode's pretax margin for the quarter that ended in Dec. 2025 was -196.47%.
The historical rank and industry rank for GENinCode's Pretax Margin % or its related term are showing as below:
LSE:GENI'
s Pretax Margin % Range Over the Past 10 Years
Min: -401.82 Med: -257.87 Max: -109.26
Current: -190.61
LSE:GENI's Pretax Margin % is ranked worse than 84.16% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs LSE:GENI: -190.61
GENinCode (LSE:GENI) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
GENinCode Pretax Margin % Related Terms
GENinCode Pretax Margin % Historical Data
* Premium members only.
The historical data trend for GENinCode's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:GENI vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, GENinCode's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GENinCode Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GENinCode's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where GENinCode's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GENinCode (LSE:GENI) has a Pretax Margin % of -196.47% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GENinCode and its competitors. According to the industry distribution chart, GENinCode ranks #170 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 84.2%.
Is GENinCode's Pretax Margin % too high?
GENinCode's current Pretax Margin % is -196.47%. Based on the distribution chart, GENinCode ranks #170 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does GENinCode's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, GENinCode ranks #170 out of 202 companies for Pretax Margin %. This places GENinCode in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on GENinCode and its competitors. GENinCode's current Pretax Margin % is -196.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GENinCode stock overvalued right now?
Based on GuruFocus' analysis, GENinCode (LSE:GENI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.04, compared to a current price of £0.01 — trading 76.8% below its estimated fair value. The current Pretax Margin % is -196.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For GENinCode (LSE:GENI), the current Pretax Margin % is -196.47% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GENinCode PLC principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes. The company has one operating segment. The company has presence in Spain, UK, United States, Italy, Germany, and Rest of World. The company generates majority of revenue from Spain. Its commercial products are CE-Marked, with CARDIO inCode, THROMBO inCode, and LIPID inCode.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:GENI has been successfully added to your 